‘Forgetting to Remember': Norwalk family shares Alzheimer's experience
NORWALK, Iowa — An Alzheimer's diagnosis is heartbreaking, and one central Iowa family has had to hear it more than once.
Luke McLaughlin still remembers growing up in Norwalk, even being crowned the homecoming king in high school.
'It's usually the football players, right? The stud football players and somehow I got it,' McLaughlin said.
His short-term memory is harder to come by because this 49-year-old is living with early-onset Alzheimer's disease.
'It feels better to get the diagnosis because then you kind of understand what's been going on and you understand why things are going the way they're going,' Tom McLaughlin, Luke's dad, said, 'but then you gotta live through it.'
Luke's family has lived through this disease before. The illness took away his mother, and is currently impacting his sister.
'You remember and see a person when they're at their best and you see them at the end of Alzheimer's and it's not easy, it's a challenge,' Shannon McLaughlin, Luke's brother, said. 'That's what I thought about with him. I don't want to see him go through the same stuff.'
'I just feel horrible for just the pain and trauma that's wreaking havoc on our family,' Luke said. 'I can't get that out of my mind.'
It's consuming for many families. Research shows nearly seven million Americans are living with Alzheimer's disease, but only 5% experience early-onset or 'younger Alzheimer's.' That's when the disease develops in your forties or fifties.
Genetic testing gave Luke that diagnosis when he was 45 years old. Over the past year, social media gave him the platform to share his story with others.
He posts short videos with help from his friend Shannon Johnson, his high school sweetheart who he reconnected with last year.
Des Moines teen soaring to new heights at prestigious flight academy
'We just started recording our phone calls and our time together, and it's really just kind of evolved naturally on its own,' Johnson said. 'But something that's really important to him is just wanting to show people how he's choosing to live his life.'
While some clips show the fun-loving dad dancing in the kitchen, others give a raw look into the realities of the disease.
A documentary titled 'Forgetting to Remember' hopes to capture that as well.
'It's not about me,' Luke said. 'It's about the disease. It's about research. It's about funding. I'm just a character in this whole documentary.'
A documentary that's started, but not yet complete.
'Clearly we're on a little bit of a ticking time bomb here,' Brent Roberts, director with The New Road Productions, said, 'where I want to be sitting next to Luke in theater to watch this. So, the sooner we can make this happen the better. And the only way we will have the time is if we have money.'
As the project gets closer to the fundraising goal, Luke's condition continues to decline.
'Early-onset Alzheimer's, people might think that it goes in a diagonal line down and people just get worse and worse and don't have the same faculties,' Luke's dad Tom explained. 'But it actually goes stair step. So, something will happen, and they'll stay in the same light for a while and you'll think 'gee this is great, they're doing well and they're getting along well.' And then all of a sudden there'll be a big drop.'
It's those moments that Luke wants to show.
'It'll create a memory, right?' Luke said. 'For my entire family and especially my young daughters. They'll see a whole new side of me.'
A time capsule of what Luke's life is like right now.
'He's so colorful and just alive,' Johnson said, 'and I want people to see him enjoying his life even though he's staring down this terrible illness.'
To provide hope for what's to come next.
'I'm here for a good time not a long time,' Luke said, 'and that's how I live.'
If you'd like to follow Luke's story, click here.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
UPI
5 hours ago
- UPI
FDA approves long-lasting HIV-prevention drug
1 of 2 | A man photographs a portion of the AIDS quilt during an HIV/AIDS rally on the National Mall in Washington, D.C., in 2021. The Food and Drug Administration has said that it has approved a new drug that could prevent HIV infections with just two shots every year. File Photo by Kevin Dietsch/UPI | License Photo June 18 (UPI) -- The Food and Drug Administration has approved a new drug that could prevent HIV infections with just two shots every year and possibly eradicate the disease. The drug's scientific name is lenacapavir and it will be marketed as Yeztugo, which requires one injection every six months to maintain its effectiveness in preventing HIV infections. Other drugs exist that also prevent HIV, but they require daily dosages in pill form and have not significantly affected the disease on a global level. "We're on the precipice of now being able to deliver the greatest prevention option we've had in 44 years of this epidemic," AVAC executive director Mitchell Warren told the New York Times. AVAC is an anti-HIV organization. He said recent funding cuts by the Trump administration will make it hard to distribute the drug globally. "It's as if that opportunity is being snatched from out of our hands by the policies of the last five months," Warren said. Gilead Sciences is producing the drug, which is the second long-lasting HIV prevention drug available. The other option is cabotegravir, which is sold under the brand name Apretude and requires an injection every two months. About 21,000 Americans use Apretude, while about 500,000 use daily oral medications to prevent HIV. Clinical trials showed most participants who received two shots of lenacapavir every year had nearly full protection against HIV. More than 39,000 people in the United States contracted HIV in 2023, which carries an estimated lifetime treatment cost of $1.1 million per patient, Gilead Chairman and Chief Executive Officer Daniel O'Day told the New York Times. Lenacapavir already is being prescribed to treat people with HIV infections that resist other medications and at an annual cost of $42,000 per patient, but most patients don't pay the full cost. Health insurance coverage and patient-assistance programs would cover the cost for most people using lenacapavir, according to Gilead. The cost for oral pills taken daily is just $1 per pill, while Apretude carries an annual cost of about $24,000. Proposed funding reductions for Medicaid and the President's Emergency Program for AIDs Relief, commonly called PEPFAR, might greatly reduce access to the drug, according to advocacy groups. The PrEP oral treatment still would be available, but it does not work for many people, Health Gap Executive Director Asia Russell told the New York Times.
Newsweek
6 hours ago
- Newsweek
Cough Syrup Recall Sparks Nationwide Warning
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Medtech Products Inc. is recalling the Little Remedies brand of Honey Cough Syrup due to fears the product may be contaminated with Bacillus cereus bacterium and concern over the product's shelf-life stability. Newsweek reached out to the company via email Wednesday for comment. Why It Matters Numerous recalls have been initiated in 2025 due to the potential of damaged products, foodborne illness, contamination and undeclared food allergens. Millions of Americans experience food sensitivities or allergies every year. According to the Food and Drug Administration (FDA), the nine "major" food allergens in the U.S. are eggs, milk, fish, wheat, soybeans, Crustacean shellfish, sesame, tree nuts and peanuts. The FDA also warns that people who consume products containing Bacillus cereus may experience nausea, vomiting or stomach cramps from one to six hours after consumption or eight to 16 hours later. "Although healthy individuals may suffer only short-term illness, exposure to high levels of foodborne B. cereus can cause death," the alert warns. What To Know In the alert, the FDA says the recalled product was distributed online and to nationwide retailers from December 14, 2022, to June 4, 2025. The alert has a chart showing UPC numbers with corresponding lot numbers and expiration dates for customers to reference. The recalled product was packaged in 4-fluid ounce bottles that are amber in color with an outside carton. Pictures of the recalled cough syrup are also in the FDA alert. The recall does not include other Little Remedies products, the agency says, adding that all lots of the Little Remedies Honey Cough 4-fluid ounce bottles "still within expiry are being included in the scope of the recall." There have been no "serious adverse events" related to the recall as of Wednesday, according to the FDA. What People Are Saying The FDA alert, in part: "Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax. Complete and submit the report Online: Regular Mail or Fax: Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178." What Happens Next Customers who have purchased the recalled cough syrup are advised to stop using the product and consult a medial professional if experiencing adverse reactions, the FDA says. Those with refund questions may contact the company via email at medicalaffairs@ by website at Link Disclaimer or via phone at (800) 754-8853 from 8:30 a.m. to 5:30 p.m. ET weekdays.
6 hours ago
Trump administration to close LGBTQ+ suicide hotline program next month
The federal government said on Tuesday it is ending the national suicide hotline's specialized support for LGBTQ+ youth next month. In a press release, the Substance Abuse and Mental Health Services Administration (SAMHSA) -- which falls under the Department of Health and Human Services -- said the 988 Suicide & Crisis Lifeline would close the LGBTQ+ Youth Specialized Services program on July 17. "The 988 Suicide & Crisis Lifeline will no longer silo LGB+ youth services, also known as the 'Press 3 option,' to focus on serving all help seekers, including those previously served through the Press 3 option," SAMHSA said in statement. "Everyone who contacts the 988 Lifeline will continue to receive access to skilled, caring, culturally competent crisis counselors who can help with suicidal, substance misuse, or mental health crises, or any other kind of emotional distress," the statement continued. "Anyone who calls the Lifeline will continue to receive compassion and help." In September 2022, 988 launched a pilot program to specifically address the needs of LGBTQ+ Americans under age 25 by providing services with a counselor trained to support LGBTQ+ youth and young adults. In March 2023, the program expanded to 24/7 services. SAMHSA data shows more than 1.2 million LGBTQ+ people contacted 988 between July 2022 -- the beginning of the new three-digit number for the national suicide hotline -- and February 2025. The Trevor Project, a nonprofit focusing on suicide prevention efforts among LGBTQ+ youth, was among those providing support for the specialized program. The organization said on Wednesday that it received notice the program was ending. "This means that, in 30 short days, this program that has provided life-saving services to more than 1.3 million LGBTQ+ young people will no longer be available for those who need it," Jaymes Black, CEO of the Trevor Project, sad in a statement. "The fact that this news comes to us halfway through Pride Month is callous -- as is the administration's choice to remove the 'T' from the acronym 'LGBTQ+' in their announcement." Studies show that youth who identify as LGBTQ+ -- lesbian, gay, bisexual, transgender, questioning or another non-heterosexual identity -- report higher rates of poor mental health and higher rates of suicidal thoughts and behaviors than their cisgender and heterosexual peers. In 2023, more than three in five LGBTQ+ high school students said they experienced persistent feelings of sadness or hopelessness, according to a 2024 report of the Youth Risk Behavior Survey, published by the Centers for Disease Control and Prevention. The report also found that 41% of LGBTQ+ youth seriously considered attempting suicide in the past year and one in five did attempt suicide. If you or someone you know is struggling with thoughts of suicide -- free, confidential help is available 24 hours a day, 7 days a week. Call or text the national lifeline at 988.
